Politics / Law, Miscellaneous, AustriaAustria

Austria to coordinate BBMRI, the world’s largest biobank resource


Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the discovery of disease-associated biomarkers, which play a major role in the development of more targeted therapeutics that show fewer side effects. “The ministers of the member states, which will financially contribute to the BBMRI (Biobanking and Biomolecular Resources Research Initiative) through their national research budgets, are going to decide next year from where the biobanking hub will be coordinated”, said Prof Kurt Zatloukal from Graz Medical University, coordinator of BBMRI’s preparatory phase. Both the Netherlands and Austria had offerd to host the initiative, but according to Zatloukal, there is no direct competition. Within its short lifetime of one and a half years, the BBMRI has already mobilised more than 30 million euros. Zatloukal also stated that it is difficult to predict how many blood and tissue samples will be available through the BBMRI after its 5-year preparatory phase, as nobody knows at this time exactly how many governments will cooperate with funding from national budgets. To date, 51 partners and 210 associated partners from 31 nations have contributed to the preparatory phase. In mid-October, the Dutch gavernment allocated EUR 22.5M to BBMRI-NL, the Dutch arm of the BBMRI (see more). Following the announcemant , online news portals wrongly reported that the Netherlands will lead the BBMRI initiative.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2015 BIOCOM



Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues